Foghorn Therapeutics (FHTX) Non-Current Deffered Revenue (2020 - 2026)

Foghorn Therapeutics' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $193.6 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 12.97% year-over-year to $193.6 million; the TTM figure through Mar 2026 stood at $193.6 million (down 12.97% YoY), while the FY2025 annual figure was $206.0 million, down 12.15% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $193.6 million, down from $206.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $317.1 million in Q1 2022, with the low at $193.1 million in Q3 2025.
• The 5-year median for Non-Current Deffered Revenue is $266.1 million (2024), against an average of $259.5 million.
• The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue surged 16324.84% in 2022, then declined 22.62% in 2025.
• Foghorn Therapeutics' Non-Current Deffered Revenue stood at $304.0 million in 2022, then dropped by 11.8% to $268.1 million in 2023, then declined by 12.55% to $234.5 million in 2024, then fell by 12.15% to $206.0 million in 2025, then declined by 6.01% to $193.6 million in 2026.
• Business Quant data shows FHTX's Non-Current Deffered Revenue at $193.6 million in Q1 2026, $206.0 million in Q4 2025, and $193.1 million in Q3 2025.